BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28431879)

  • 1. Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.
    Dong S; VanGelder K; Shi ZC; Yu Y; Wu Z; Ferguson R; Guo ZZ; Tang H; Frie J; Fu Q; Gu X; Priest BT; Thomas-Fowlkes B; Weinglass A; Margulis M; Liu J; Pai LY; Hampton C; Haimbach RE; Owens K; Tong V; Xu S; Hu M; Zingaro GJ; Morissette P; Ehrhart J; Roy S; Sullivan K; Pasternak A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2559-2566. PubMed ID: 28431879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.
    Chobanian HR; Guo Y; Pio B; Tang H; Teumelsan N; Clements M; Frie J; Ferguson R; Guo Z; Thomas-Fowlkes BS; Felix JP; Liu J; Kohler M; Priest B; Hampton C; Pai LY; Corona A; Metzger J; Tong V; Joshi EM; Xu L; Owens K; Maloney K; Sullivan K; Pasternak A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1109-1114. PubMed ID: 28111141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.
    Richter JM; Gunaga P; Yadav N; Bora RO; Bhide R; Rajugowda N; Govindrajulu K; Godesi S; Akuthota N; Rao P; Sivaraman A; Panda M; Kaspady M; Gupta A; Mathur A; Levesque PC; Gulia J; Dokania M; Ramarao M; Kole P; Chacko S; Lentz KA; Sivaprasad Lvj S; Thatipamula RP; Sridhar S; Kamble S; Govindrajan A; Soleman SI; Gordon DA; Wexler RR; Priestley ES
    J Med Chem; 2024 Jun; 67(11):9731-9744. PubMed ID: 38807539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.
    Walsh SP; Shahripour A; Tang H; de Jesus RK; Teumelsan N; Zhu Y; Frie J; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Ehrhart J; Roy S; Kaczorowski GJ; Yang L; Garcia ML; Pasternak A
    Bioorg Med Chem Lett; 2016 May; 26(9):2339-43. PubMed ID: 27017115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.
    Zhu Y; de Jesus RK; Tang H; Walsh SP; Jiang J; Gu X; Teumelsan N; Shahripour A; Pio B; Ding FX; Ha S; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Ehrhart J; Roy S; Kaczorowski GJ; Yang L; Parmee ER; Sullivan K; Garcia ML; Pasternak A
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5695-5702. PubMed ID: 27839686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.
    Jiang J; Ding FX; Zhou X; Bateman TJ; Dong S; Gu X; Keh deJesus R; Pio B; Tang H; Chobanian HR; Levorse D; Hu M; Thomas-Fowlkes B; Margulis M; Koehler M; Weinglass A; Gibson J; Houle K; Yudkovitz J; Hampton C; Pai LY; Samuel K; Cutarelli T; Sullivan K; Parmee ER; Davies I; Pasternak A
    J Med Chem; 2021 Jun; 64(11):7691-7701. PubMed ID: 34038119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
    Tang H; de Jesus RK; Walsh SP; Zhu Y; Yan Y; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Roy S; Kaczorowski GJ; Yang L; Garcia ML; Pasternak A
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5829-32. PubMed ID: 24075732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.
    Hampton C; Zhou X; Priest BT; Pai LY; Felix JP; Thomas-Fowlkes B; Liu J; Kohler M; Xiao J; Corona A; Price O; Gill C; Shah K; Rasa C; Tong V; Owens K; Ormes J; Tang H; Roy S; Sullivan KA; Metzger JM; Alonso-Galicia M; Kaczorowski GJ; Pasternak A; Garcia ML
    J Pharmacol Exp Ther; 2016 Oct; 359(1):194-206. PubMed ID: 27432892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics.
    Aretz CD; Vadukoot AK; Hopkins CR
    J Med Chem; 2019 Oct; 62(19):8682-8694. PubMed ID: 31034224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis.
    Garcia ML; Priest BT; Alonso-Galicia M; Zhou X; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Liu J; Swensen A; Pai LY; Xiao J; Hernandez M; Hoagland K; Owens K; Tang H; de Jesus RK; Roy S; Kaczorowski GJ; Pasternak A
    J Pharmacol Exp Ther; 2014 Jan; 348(1):153-64. PubMed ID: 24142912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inwardly rectifying potassium channel Kir1.1: development of functional assays to identify and characterize channel inhibitors.
    Felix JP; Priest BT; Solly K; Bailey T; Brochu RM; Liu CJ; Kohler MG; Kiss L; Alonso-Galicia M; Tang H; Pasternak A; Kaczorowski GJ; Garcia ML
    Assay Drug Dev Technol; 2012 Oct; 10(5):417-31. PubMed ID: 22881347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease.
    Garcia ML; Kaczorowski GJ
    Curr Opin Pharmacol; 2014 Apr; 15():1-6. PubMed ID: 24721647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of oxadiazole-based FLAP inhibitors.
    Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the renal outer medullary potassium channel: a patent review.
    Martelli A; Testai L; Breschi MC; Calderone V
    Expert Opin Ther Pat; 2015; 25(9):1035-51. PubMed ID: 26004420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel.
    Bhave G; Chauder BA; Liu W; Dawson ES; Kadakia R; Nguyen TT; Lewis LM; Meiler J; Weaver CD; Satlin LM; Lindsley CW; Denton JS
    Mol Pharmacol; 2011 Jan; 79(1):42-50. PubMed ID: 20926757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation.
    Ng CF; Koon CM; Cheung DW; Lam MY; Leung PC; Lau CB; Fung KP
    J Ethnopharmacol; 2011 Oct; 137(3):1366-72. PubMed ID: 21855622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.
    Tang H; Zhu Y; Teumelsan N; Walsh SP; Shahripour A; Priest BT; Swensen AM; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Pai LY; Hampton C; Corona A; Hernandez M; Metzger J; Forrest M; Zhou X; Owens K; Tong V; Parmee E; Roy S; Kaczorowski GJ; Yang L; Alonso-Galicia M; Garcia ML; Pasternak A
    ACS Med Chem Lett; 2016 Jul; 7(7):697-701. PubMed ID: 27437080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.
    Chen A; Aspiotis R; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Falgueyret JP; Gagné S; Han Y; Houle R; Laliberté S; Larouche G; Lévesque JF; McKay D; Percival D
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7399-404. PubMed ID: 22071301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.